Kaempferol mitigates Endoplasmic Reticulum Stress Induced Cell Death by targeting caspase 3/7

Ahmad Abdullah & Palaniyandi Ravanan

The Endoplasmic Reticulum (ER) plays a fundamental role in executing multiple cellular processes required for normal cellular function. Accumulation of misfolded/unfolded proteins in the ER triggers ER stress which contributes to progression of multiple diseases including neurodegenerative disorders. Recent reports have shown that ER stress inhibition could provide positive response against neuronal injury, ischemia and obesity in *in vivo* models. Our search towards finding an ER stress inhibitor has led to the functional discovery of kaempferol, a phytoestrogen possessing ER stress inhibitory activity in cultured mammalian cells. We have shown that kaempferol pre-incubation significantly inhibits the expression of *GRP78* (a chaperone) and *CHOP* (ER stress associated pro-apoptotic transcription factor) under stressed condition. Also, our investigation in the inhibitory specificity of kaempferol has revealed that it inhibits cell death induced by diverse stimuli. Further study on exploring the molecular mechanism implied that kaempferol renders protection by targeting caspases. Both the *in silico* docking and *in vitro* assay using recombinant caspase-3 enzyme confirmed the binding of kaempferol to caspases, through an allosteric mode of competitive inhibition. Altogether, we have demonstrated the ability of kaempferol to alleviate ER stress in *in vitro* model.

Apoptosis is a quintessential signaling pathway which occurs physiologically during development and maintains normal cellular homeostasis. In contrast, its dysregulation under pathological conditions ranges from cancer resulting due cells evading apoptosis to disorders involving extensive cell loss. Imbalance in cellular proteostasis due to accumulation of misfolded or unfolded proteins triggers signaling pathways in ER called UPR. When ER overwhelms with protein load, *GRP78* (78 kDa glucose-regulated protein) dissociates from and activates ER transmembrane proteins: PERK (RNA-like endoplasmic reticulum kinase), ATF6 (Activating transcription factor 6) and IRE1α (Inositol requiring enzyme 1 alpha). UPR primarily fires pro-survival signal transduction pathways aiming to restore homeostasis by decreasing the protein load in ER simultaneously enhancing the machinery for protein folding and degradation. However if the attempt fails, the UPR triggers cell death via apoptosis.

Prolonged activation of ER stress contributes to the development and progression of several pathological conditions. These include neurodegenerative diseases, stroke, cardiovascular diseases, obesity, diabetes, cancer, immune disorders, atherosclerosis and liver diseases. There are increasing *in vivo* experimental evidences suggesting that alleviating ER stress demonstrates therapeutic potential. Significant improvement have been observed after administration of ER stress inhibitors in *in vivo* models of neuronal injury, cardiovascular disease, hypertensive chronic kidney disease, LPS induced lung inflammation, renal ischemia reperfusion injury, post traumatic brain injury, spinal cord injury and sleep apnea.

Identification of small molecule inhibitors that can target UPR machinery and reduce ER stress has drawn considerable attention. In the past, several compounds potentially modulating ER stress have been reported. For example, 4-PBA and TUDCA (chemical chaperones), salubrinal (inhibitor of dephosphorylation of eIF2α), valproate (inducer of chaperones without evoking the UPR) and benzodiazepinones (modulators of ASK1) have been extensively studied.

Many of the current therapeutic drugs marketed have their discovery rooted in traditional medicine as they are either unaltered natural products or their modified synthetic analogues with improved efficiencies. The very same reason has intrigued researchers to screen herbal plants, isolate, identify and evaluate their bioactive compounds as leads for potential drugs. Tailoring the natural products to enhance their potency, availability,
selectivity and various other properties have introduced several clinically therapeutic drugs. Liu et al. have described several naturally occurring saponins, alkaloids and polyphenols that regulate ER stress induced cell death via apoptosis and autophagy. Alternatively, flavonoids are natural antioxidants that have been reported to exert neuroprotective functions in several cell lines and in vivo models.

In the present study, we performed a small scale screening of selected bioactive compounds and identified a flavonoid, kaempferol, possessing ER stress inhibitory activity in vitro. We are the first to report that kaempferol reversed the effects of Brefeldin A (BFA) which is a classic ER stress inducer. Further study on elucidating the working mechanism of kaempferol has revealed that it inhibits BFA induced apoptosis by inhibiting the activity of caspases and maintains the expression of cIAPs in cultured mammalian cells.

Results
Kaempferol attenuated ER stress induced cell death in multiple cell lines. Because ER stress induced cell death is associated with multiple neurodegenerative diseases, we focused our small scale screening of phytocompounds for the ER stress inhibitory activity on human neuroblastoma cell line IMR32. The selection of phytocompounds was based on the plant extracts which are used in traditional Indian medicine for the treatment of neurological disorders. To screen for ER stress inhibitors, IMR32 cells were pre-incubated with the test compounds for 90 minutes and treated with ER stress inducer BFA, incubated for 24 h. Cell viability was estimated by MTT assay. BFA: Brefeldin A; Withan: Withanone; With A: Withanaloide A; With B: Withanaloide B; kaemp: kaempferol; kaempG: Kaempferol-3-O-robinobioside-7-O-glucoside; Bacop I: Bacopaside I; PEA: Palmitoylthetanolamide; PBA: Phenyl Butyric acid; Sal: Salubrinal. (b) Confirmation of cytoprotective activity of kaempferol by measuring cellular ATP level using CellTiter Glo reagent. (c) Phase contrast images of IMR32 cells after BFA treatment in presence or absence of kaempferol pre-incubation. (d-f) Cytoprotective activity of kaempferol against BFA induced cell death in multiple cell lines with incubation time of 24 hours. Cell viability was assessed using MTT assay. (g) Inhibition of caspase 3/7 activation by kaempferol against BFA and CDDO-Me induced caspase 3/7 activation in IMR32 cells. Data represents mean ± SEM of experiment performed in triplicate (n = 3). Note: *Represents the significance between cell death inducer alone treated condition compared to kaempferol pre-treated condition, at p ≤ 0.05 (one way ANOVA).
and trypan blue dye exclusion assay as a surrogate for the cell viability (Fig. 1b and Supplementary Figure 4a). Furthermore, typical characteristics like cell shrinkage and cell detachment was observed in BFA treated cells. However, considerably large number of kaempferol pretreated cells displayed healthy cellular morphology compared to BFA treated cells (Fig. 1c). Because kaempferol exhibited cytotoxicity at higher concentrations, we have set 50 µM as the maximum concentration for further analysis (Supplementary Figure 2b). Furthermore, kaempferol exhibited protection against multiple ER stress inducing stimuli in other cancer cell lines (MDA-MB-468, HeLa, MCF-7 and Neuro2A) as well (Fig. 1d,e and f and Supplementary Figure 2c–f). Reimertz et al., has demonstrated that ER stress induced cell death is caspase dependent in neuronal cells30; hence we investigated the effect of ER stress on the activity of caspase 3/7 using commercially available Glo-caspase 3/7 assay kit (Promega, India) in IMR32 cells. Our result indicated that, both BFA and CDDO-Me induced the caspase3/7 activity and kaempferol reduced the activity into half (Fig. 1g). We used ZV AD-FMK, a pan caspase inhibitor as a positive control. Collectively, these preliminary results showed that kaempferol attenuates cell death induced by various ER stress inducers in multiple cell lines perhaps due to inhibition of caspase 3/7 activity.

Previous studies have demonstrated that kaempferol is a phytoestrogen (Estrogen receptor β agonist)31. Therefore, we tested whether PHTPP (a selective ER β antagonist) has any effect on protection yielded by kaempferol. As shown, CellTiter-Glo luminescent cell viability assay (Supplementary Figure 3a) as well as caspase 3/7 activity assay (Supplementary Figure 3b) results revealed that the ER β antagonist couldn't reverse the protection exerted by kaempferol, suggesting that kaempferol did not require active estrogen receptor signaling pathway to inhibit BFA induced cell death. Simultaneously, we tested if another ER β antagonist DPN (Diarylpropionitrile) and the estrogen (17β-estradiol) reduces BFA induced caspase 3/7 activity in IMR32 cells. As shown in Supplementary Figure 3c, Estrogen receptor modulators failed to inhibit caspase 3/7 activity (Supplementary Figure 3c). These findings suggest that kaempferol inhibits ER stress induced apoptosis in multiple cell lines; the anti-apoptotic effect of kaempferol is mediated via inhibition of caspase 3/7 activity and it is estrogen receptor signaling independent.
Mapping the UPR/apoptotic pathways regulated by kaempferol. ER stress triggers UPR signaling cascade which is initiated by GRP78, a master regulator in association with IRE1α, PERK and ATF6 (reviewed in Chaudhari et al., 2014)32. We performed real time quantitative RT-PCR (q-RT-PCR) and immunoblotting to study the impact of kaempferol in the regulation of UPR signal transduction pathways. As shown in Fig. 2 and Supplementary Figure 4b, BFA induced the expression of GRP78, IRE1α, PERK and ATF6; however, the cells pre-incubated with kaempferol showed significant reduced expression level of GRP78 and ATF6 mRNA, while IRE1α and PERK expression was not significantly altered in IMR32 cells (Fig. 2a). GRP78 induction is considered as a marker for ER stress, showed reduced expression in protein level in kaempferol pretreated cells (Fig. 2b). Recent study published by Guo et al. showed kaempferol induces ER stress, thereby inducing cell death in HepG2 hepatocellular carcinoma cells33. In our study, although higher concentration of kaempferol (100 µM) exhibited cytotoxicity, it failed to induce Grp78 expression in IMR32 neuroblastoma cells and reduced BFA induced expression of Grp78 levels (Supplementary Figure 4c,d). Therefore the activation of ER stress by kaempferol reported in other tumor cell lines might be a cell line specific and concentration dependent event but not a general mode of action by kaempferol. Moreover, the authors have mentioned the apoptotic activity as concentration and time dependent in HepG2 cells. Bax and SIRT3 activation, p53 activation and ROS generated oxidative stress are other mode of kaempferol induced cell death reported in various tumour cell lines34–36. All three UPR signaling events finally converge into the activation of CHOP (C/EBP homologous protein), a pro-apoptotic transcription factor that induces apoptosis by modulating the expression of several genes including Death Receptor-DR5 (a known CHOP target gene), pro-apoptotic gene Bim (Bcl-2 interacting mediator of cell death) and anti-apoptotic gene Bcl-2 (B-Cell Lymphoma-2). In this aspect, CHOP has been shown to induce the expression of Bim while reducing the expression of Bcl-2. As shown in Fig. 2a and c, pre-treatment with kaempferol considerably attenuated BFA induced upregulation of CHOP mRNA levels in two different cell lines (IMR32 and MDA-MB-468).

Depending on the intensity and duration of ER stress, IRE1α activates various stress signals including JNKs (c-Jun N-terminal kinase) and P38 MAPK (Mitogen activated protein kinase) which can eventually lead to cell death. To measure the p38MAPK activation, immunoblotting was performed. As shown, BFA induced both p38MAPK and phosphorylated p38MAPK while, kaempferol reduced the activation partially at 6 h but we did not observe any change in the levels of p38 at 3 h and 12 h (Fig. 3a,b). PERK activation initiates a trans-lational arrest by phosphorylating the eIF2α and thereby decreasing the ER protein load. Treatment of cells with kaempferol increased the level of phospho-eIF2 α alpha, suggesting that this mechanism could contribute to the protection exerted by kaempferol against BFA induced ER stress.

Figure 3. Kaempferol regulates ER stress induced apoptotic signaling. (a) IMR32 cells were treated with BFA in presence or absence of kaempferol pre—incubation for 3 h, 6 h and 12 h. Lysates were prepared, normalized for total protein content, and analyzed by immunoblotting using antibodies specific for p-p38-MAPK, p38-MAPK, p-eIF2αα. (b) Densitometry analysis of ratio of phospho to non-phosphorylated levels of p38 MAPK and eIF2αα. Data represents ratios of the average ± SEM of two independent experiments (n = 2). (c) Regulation of Bim, Bcl2 and DR5 gene expression upon BFA treatment in presence and absence of Kaempferol pre-treatment. Data represented as mean ± SEM of two independent experiments performed in duplicate. *Represents the significance with respect to control cells (p ≤ 0.05 (one way ANOVA)).
Figure 4. Kaempferol maintains cIAPs and inhibits caspase 3/7 activation. (a,b) Expression of cIAP1 and cIAP2 mRNA level was measured by q-RTPCR. ER stress was induced in IMR32 cells with BFA in the presence and absence of kaempferol pre-treatment. Expression of cIAPs level was compared to caspase 3/7 activation in 12 h and 24 h of ER stress induction. Data represented as average ± SEM of two independent experiments performed in duplicate. * Represents the comparison of BFA treated condition to control cells; † represents the significant difference between BFA treated cells to BFA + kaempferol pre-treatment at p ≤ 0.05. (c) Regulation cIAPs mRNA level at increasing treatment hours in IMR32 cells cultured with BFA with/without kaempferol pre-treatment. Data represented as average ± SEM of two independent experiments performed in duplicate. (d,e) Protein levels of cIAP1 and cIAP2 in IMR32 cells after 24 hours of treatment with BFA and kaempferol pre-treated conditions by immunocytochemistry (Scale bar: 67 µm). (f) MTT assay showing the reversal of cell death protection by SMAC mimetic compounds co-treatment with KFL + BFA treated cells after 24 hours of incubation. (g) SMAC mimetic increases the caspase 3/7 activity in IMR32 cells upon treated with BFA alone and in BFA + KFL combination. Data
represented as average ±SEM of two independent experiments performed in triplicate. * and † Represents significance at p < 0.05 with respect to BFA treated cells and *Represents significance at p < 0.05 with respect to BFA + KFL treated cells (One-way ANOVA).

In IMR32 cells, BFA up regulated DR5 mRNA expression. This finding has been previously reported in various cell types using different ER stress inducers.20,27 Interestingly, similar to BFA, kaempferol treatment also induced the expression of DR5. In spite of significant upregulation of DR5 level in kaempferol alone treated cells, we did not observe activation of caspase 3/7 (Supplementary Figure 3c) suggesting that DR5 upregulation did not have any effect on caspase 3/7 activation and cell death in IMR32 cells. Pertaining to Bcl-2 gene expression, BFA treatment alone reduced Bcl-2 expression while pre-incubation with kaempferol decreased the expression further. Notably, kaempferol alone did not change the expression of Bcl-2 and Bim (Fig. 3c). Collectively these results indicate that kaempferol decreases the mRNA expression of certain BFA regulated genes involved in ER stress and cell death with simultaneous inhibition of BFA activated stress kinases.

Inhibition of caspase 3/7 activity by kaempferol maintains the expression of IAPs in IMR32 cells.

The family of cysteine proteases named caspases is critical mediators of apoptosis. Caspases are mainly divided into initiator caspases (caspase-8, -9 and -12) and executioner caspases (caspase-3, -6, and -7). In ER stress induced cell death, caspase-12 has been demonstrated as the initiator caspase while procaspase-9 has been shown as substrate for caspase-12.26 Caspases activation can be further regulated by endogenous inhibitors of apoptosis proteins (IAPs) and SMAC/Diablo. IAPs are conserved throughout animal evolution and several IAP-family proteins have been shown to directly bind and inhibit the activity of caspases, thereby suppressing apoptosis. Evidences support that increased cIAPs (cellular inhibitor of apoptosis protein) levels protect cells against apoptotic stimuli.27 Hence, we sought to investigate if kaempferol regulated IAPs as a self-defense mechanism against ER stress induced cell death. We studied the mRNA expression profile of cIAP1, cIAP2, XIAP (X-linked inhibitor of apoptosis protein) and survivin after treatment with BFA in presence and absence of kaempferol. Our results showed that BFA treatment induced cIAP1 and cIAP2 mRNA level to 5 and 55 folds respectively at 12 hours which was reduced to 3 and 10 folds respectively in kaempferol pre-treated cells. Similarly, BFA increased the levels of cIAP1 and cIAP2 to 1.5 and 20 folds respectively at 24 hours, but for kaempferol pre-treated cells, cIAPs levels remained relatively stationary (Fig. 4a–c). We analysed the protein level of cIAPs using immunocytochemistry and results showed that there is a reduction in cIAPs protein level in BFA treated cells despite a high induction in mRNA level. However, in kaempferol pre-treated condition the cIAPs expression was not altered in both mRNA level and protein level between 12 and 24 hours after the induction of ER stress (Fig. 4d,e and Supplementary Figure 6). Analysis of active caspase 3/7 showed that BFA treatment increased the caspase 3/7 activity in 12 hours to 2 folds, whereas we observed simultaneous hike in cIAP1 (~6 fold) and cIAP2 (~50 fold) levels. But, after 24 hours of BFA treatment we observed an elevation in caspase 3/7 activity to 8 folds with a fall in cIAP1 (~1.5 fold) and cIAP2 (~20 fold) mRNA expression. As shown in Fig. 4c BFA induced expression of cIAPs mRNA could be an adaptive mechanism to overcome ER stress induced apoptosis. In kaempferol pre-treated cells, the activity of caspase 3/7 by BFA was inhibited significantly to the level of 1.4 and 24 fold at 12 and 24 hours respectively (Fig. 4a,b). Both the cIAPs expression level was maintained in kaempferol pre-treated cells; this suggests the inhibitory action of kaempferol on caspases, which otherwise had to be done by increase in the levels of cIAPs expression.26 We also observed that kaempferol treatment alone did not induce caspase 3/7 activation despite kaempferol known to cause cell death at higher concentration (Supplementary Figure 3c). Similarly, kaempferol did not alter other IAPs like XIAP and survivin gene expression in IMR32 cells (Supplementary Figure 5), which corresponds to the study published by Harlin et al., on an increase of cIAPs expression in XIAP deficient mice.41 Taken together, these results suggest that kaempferol inhibits caspase 3/7 activity and maintains the levels of cIAPs in IMR32 cells.

IAPs antagonist (SMAC mimetics) reverses the protection by kaempferol.

SMAC mimetics are small molecules which inhibit the activity of IAPs by directly binding to the shallow groove on the surface of IAP’s BIR domains or indirectly inhibits by inducing auto-ubiquitination followed by proteasomal degradation of IAPs.42 Using commercially available SMAC mimetic compounds (GDC0152, LC 161, MedChem Express) we tested if these compounds reverse the ER stress inhibitory activity of kaempferol. IMR32 cells were pre-incubated with SMAC mimetics and kaempferol for 90 minutes each and ER stress was induced with BFA. As shown in Fig. 4f,g viability assay and caspase 3/7 activity assay confirmed that both the SMAC mimetics could reverse the kaempferol induced ER stress inhibition suggesting that IAPs are partly involved in protection mediated by kaempferol. Also, SMAC mimetics alone treated cells did not exhibit cell death as these compounds often require addition of death ligands such as TNFα or TRAIL for the induction of cell death.43 As expected, BFA induced the cell death as well as caspase 3/7 activity in IMR32 cells while kaempferol pretreatment inhibits both. We observed a significant increase of cell death in BFA + LC161 condition when compared to the BFA alone suggesting that IAP inhibition increases BFA induced caspase activity. Additionally, we observed that kaempferol slightly reduced BFA + LC161 induced caspase activity. ZVAD-FMK was served as a positive control for the caspase 3/7 inhibition.

Kaempferol alleviates cell death induced by multiple stimuli through the inhibition of caspases.

Considering the fact that caspases are involved in cell death induced by various stimuli, we questioned the specificity of kaempferol in inhibiting cell death/apoptosis. To determine, kaempferol’s anti-apoptotic activity is specific to ER stress induced cell death versus general inducers of cell death, we challenged IMR32 and MDA-MB-468
cells to various cell death inducing stimuli, such as TNF-α (a cytokine and cell signaling protein)/Cycloheximide (protein synthesis inhibitor), Staurosporine (pan-kinase inhibitor) and Doxorubicin (DNA-intercalating agent).

Our results showed that kaempferol inhibits apoptosis induced by multiple stimuli (Fig. 5a–g) confirming that kaempferol may target a key player which is common to most forms of cell death such as caspases. 

In contrast to our result, kaempferol has been widely reported to induce cell death in multiple cell lines by inducing the cleavage of caspase zymogens which was shown by western blot. However, the authors failed to test the activity of caspases after the cleavage of caspase-3 which implies that flavonoids may be inhibiting the active form but the cell death is happening possibly via caspase independent mechanism44–47. Additionally, induction of cell death in caspase-3−/−/caspase-7−/− mouse embryonic fibroblasts (MEF) treated with flavonoids did not show any significant difference in extents of cell death when compared to the wild type MEF cells. These results suggest that, the mechanism of flavonoid induced cytotoxicity is unclear and may involve a caspase independent form of cell death48.

Kaempferol binds to the dimerization interface of caspases. We then employed in silico approach (blind docking method) to check if kaempferol efficiently binds to caspase-7 enzyme which shares 53% of sequence identity and 100% (16 out of 16) of the amino acids facing the central core of the enzyme dimer with caspase 349. Both the caspases have same substrate preference as well50. Docking with crystal structure of caspase-7 (PDB ID: 4FEA) showed the binding of kaempferol to the dimerization site through H-bonding interaction with the Cys 290 residue (Fig. 6a) which is crucial for the active dimer conformation49. The docking studies revealed the interaction of kaempferol in the same binding site as of 0TE a known pan-caspase inhibitor (Fig. 6b). Moreover, we observed the presence of hydrophobic interactions with Val 292 and Met294, which are shown to have a prominent role in binding to the pan caspase inhibitor 0TE50. The comparative studies with the docked pose of crystal structure of DICA bound caspase-7 complex (Fig. 6c) also showed that the docked pose of kaempferol signifies a valid mode of caspase inhibition. The solid surface representation of caspase-7 enzyme with docked poses of 0TE, kaempferol and DICA shows the binding of the compounds into the same allosteric site of caspase-7 dimer (Fig. 6d). Docking scores obtained for kaempferol (∆G = −4.01 kcal/mol) showed significant binding energy as of 0TE (∆G = −2.83 kcal/mol) re-docked to caspase-7 crystal structure (PDB ID: 4FEA).

We also examined binding of kaempferol to caspase-3 by docking the compound against the crystal structure of caspase-3 with PDB ID: 3DEJ. Since there is no crystal structure of allosteric inhibitor bound to caspase-3
dimerization sites available on PDB, the docked complex was compared to docked complex of 0TE. In both the
dockings, there was no interaction found with Cys residue present at the dimerization site. But the LigPlot anal-
ysis showed H-bonding for 0TE and kaempferol at Arg 164, Tyr 197 and Glu 124, Arg 164, Thr 140, Tyr 195 of
caspase-3 respectively. Moreover, hydrophobic interactions with Val 266, Lys 137, Leu 136, Pro 201 and Gly 125 were
also observed (Supplementary Figure 7a–c). Studies performed by Walters et al., showed that the mutant V266H
caspase-3 causes conformational changes which propagates through the structure and inactivates the enzyme. In the
same study, the mutation of Glu 124 and Tyr 197 also showed reduced enzymatic activity. In total the residues Glu 124
and Tyr 197 are involved in the stabilization of Arg 164 residue of the monomer51. The surface representation
of caspase-3 enzyme structure with superimposed docked poses of 0TE and kaempferol shows that the compounds
sharing the same binding pocket at dimerization site, as predicted by docking studies (Supplementary Figure 7d).
Thus, the docked complex of 0TE and kaempferol showed interactions with amino acid residues required for the
formation of an active caspase-3 dimer thereby may have an active role in the inhibition of enzymatic activity.

Next, docking study was performed on binding of kaempferol to caspase-9 monomer. Our results showed that
kaempferol binds to the binding region of BIR3 domain of XIAP protein on caspase-9 monomer (PDB ID: 1NW9)
(Supplementary Figure 8a,b). Activation of caspase-9 requires the dimerization of monomers, which was shown
to be held inactive by the hetero-dimerization with XIAP-BIR3 domain interacting via Vander Waal’s interaction
toLeu384, Leu385, Ala388, and Cys403 residues of caspase-9 monomer52. These amino acid residues which are
involved in the event of caspase-9 dimerization (for its active state dimer) are being intercepted by the binding of
kaempferol (Supplementary Figure 8c). Gln 388 and 381 of caspase-9 forms a hydrogen bond to the hydroxyl moiety
of kaempferol, while the 2D interaction analysis with Ligplot + showed the hydrophobic interactions with Leu 384,
Ala 388, Met 400, Pro 401 and Cys 403 residues of caspase-9 monomer (Supplementary Figure 8d).
Since kaempferol is a known ERβ agonist, we performed the docking analysis for other well-known ERβ mod-
ulators like 17β-estradiol, DPN and PHTPP (4-[2-Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]
phenol). 17β-estradiol showed no favorable interaction with caspase-3 and 7 enzymes in docking studies. DPN
and PHTPP interact effectively with caspases-3, 7 & 9 and the results have been tabularized (Supplementary
Table 1).

Figure 6. Kaempferol binds to the caspase-7 dimerization site: In silico analysis. (a) LigPlot + analysis (2D
representation) of docked complexes of 0TE and kaempferol compared to crystal structure (PDB ID: 1SHJ) of
DICA docked pose with caspase 7 enzyme dimerization site. Red circles represents the amino acid residues
common to the binding site of 0TE and DICA, obtained by docking studies with kaempferol. Green dotted lines
represents H-bonding (kaempferol) in docked complex and violet solid line (DICA) represents the covalent
bonding as represented in the crystal structure. (b) Superimposed structures of 0TE and kaempferol docked
decomplexes as represented by UCSF Chimera. (c) 3D representation of docked poses of 0TE, kaempferol and
DICA using PYMOL (Cysteine ●; Valine ○; Methionine ● ) (d) Solid Surface representation of caspase-7 dimer
with 0TE ●; kaempferol ○; and DICA ○; docked poses superimposed at the dimerization site.
Inhibitory action of kaempferol against human active caspase-3 enzyme. We subsequently performed in vitro assay to study the direct inhibitory activity of kaempferol on caspase-3 using the recombinant active caspase-3 enzyme (Enzo life Sciences) and caspase 3/7 activity assay kit (Promega, India). As shown in Fig. 7a,b, the activity of caspase-3 was inhibited by kaempferol in a dose dependent manner and the IC50 value was assessed to be 5.65 µM (Fig. 7c). The Michaelis-Menten study for Vmax and Km showed an increase in Km value with increasing concentration of kaempferol (Table 1), revealed the kaempferol’s competitive mode of inhibition. We used Ac-DEVD CHO, a known peptide inhibitor of caspase-3 as a positive control. Additionally, we tested other ER β modulators for their ability to inhibit caspase-3 activity. Although a high dock score was obtained for these compounds, they failed to reflect in in vitro enzymatic assay performed using purified recombinant caspase-3 enzyme. We validated the docking data for DPN, PHTPP and 17β-estradiol also. The results showed that all three compounds were not able to inhibit the caspase-3 activity. However, DPN and PHTPP reduced the caspase-3 activity moderately at very high concentration (150 µM), whereas 17β-estradiol did not inhibit caspase-3 even at 150 µM concentration (Supplementary Figure 9a-e).

Further studies on, whether the inhibition of caspase 3 activity inhibiting the cleavage of caspase-3 downstream targets, we checked the level of XIAP, a target of the caspase-3 enzyme. The studies performed by Walsh JG et al., showed preference of caspase-3 enzyme for XIAP over caspase 76, and Hornle et al., had shown the cleavage of XIAP by caspase-3 as a prerequisite for its proteasomal degradation54, having a predicted cleavage site motif of RSESD-AVSSD, with SNP at Asp242Glu55. The results of immunocytochemistry showed the inhibition of XIAP degradation in BFA treated condition in the presence of kaempferol. Although the positive control for caspase-3 inhibitory activity Z-VAD-FMK couldn’t rescue the cell death induced by BFA, there observed higher levels of XIAP than BFA alone treated cells (Fig. 7e). Therefore the inhibition of caspase-3 activity rescues the target protein XIAP levels in cells pretreated with kaempferol.

Discussion
Flavonoids are polyphenolic compounds often found in plant that contribute significantly in human diet especially via dietary sources like tea, wine, legumes, vegetables and fruits. Flavonoids have been consumed traditionally as folklore medicine. Previous reports suggest the diversified biological activities of flavonoids which include anti-inflammatory, anti-carcinogenic and anti-oxidative stress abilities. Kaempferol is an abundantly found flavonoid in edible and medicinal plants. It exhibits various pharmacological activities like antioxidant, anti-inflammatory, antimicrobial, anticancer, cardio-protective, neuroprotective, antidiabetic, anti-osteoporotic, estrogenic/anti-estrogenic, anxiolytic, analgesic and anti-allergic activities28.

The present study showed the ability of kaempferol, plant derived ER β agonist to inhibit ER stress induced cell death in cultured mammalian cells. This is consistent with the evidence that kaempferol inhibits the expression of certain key genes that regulate the UPR pathways. In this regard, we showed that kaempferol significantly decreased the BFA induced mRNA expression of UPR markers like GRP78 and CHOP in IMR32 and MDA-MB-468 cells. Furthermore, eIF2α and downstream elements of UPR pathway molecules like p38 MAPK have also been regulated by kaempferol. The stress kinase p38 MAPK and CHOP have been known to induce the expression of pro-apoptotic gene Bim and down-regulate the anti-apoptotic gene Bcl-2 under ER stress conditions. In our study, both BFA alone and kaempferol pretreated cells has decreased the mRNA expression level of Bcl-2 and Bim. The activation of caspase-3 was shown to degrade Bim in mouse osteoblast cells56. Therefore, the reduction in Bim expression level can be attributed to high caspase activation with BFA in IMR32 cells.

Several studies have suggested that flavonoid compounds induce apoptosis of cancer cells and does not induce cell death of normal cells; in our study, kaempferol treatment did not change the activity of caspase 3/7 in neuroblastoma and in other cancer cells at 50 µM concentration; the effect of kaempferol in normal cells yet to be tested. Caspases are known to get activated during ER stress and they are essential for ER stress induced cell death. It has been shown that caspase 9 inhibitor repress ER stress induced cell death in primary neuronal cells following hypoxia/reperfusion induced ER stress56,57. A very recent study showed that ZVAD-FMK also inhibited ER stress. Furthermore, it has been demonstrated in the same study that ER stress downregulated many caspase substrates at the protein level; caspases influenced ER stress pathway both by directly cleaving its substrates and also by deactivating transcription factors essential for upregulation of genes involved in cell fate decisions58.

In our study, while investigating the specificity of the compound, we identified and realized that kaempferol inhibits cell death induced by multiple stimuli. Although kaempferol is not specific against ER stress induced cell death, it plays an interesting role of targeting caspases. Results of structural analysis using in silico approach as well as biochemical and kinetic studies using recombinant caspase enzyme strongly support the fact that a common allosteric mechanism is the base for caspase inhibition by kaempferol. Kaempferol is expected to bind to the dimerization interface and change the conformation of caspases and thereby affect the catalytic activity. However, this remains a hypothesis as we do not have direct evidence to support it by crystallographic study. Besides the demand for a high expense by its potency, the caspase inhibiting ability of this commonly occurring dietary flavonoid can be considered for therapeutic application. Furthermore, several reports have shown the association of ER stress and therapeutic opportunity of caspase inhibitors to neurodegenerative diseases. Currently, available inhibitors of caspases are mostly peptide based and are mainly used for research purpose; the synthetic peptide mimicking orthosteric inhibitors are shown to form toxic products during the course of metabolism in vivo59. In this study, the inhibition of caspase activation with ZVAD-FMK showed increased cell death in IMR32 cells induced with BFA (data not shown). Therefore, kaempferol may be evaluated further as ER stress/non-peptide caspase inhibitor.
Introducing caspase inhibitors particularly peptide based, as safe and effective therapeutics may face a lot of challenges considering multiple variables like specificity, selectivity, understanding the contribution of caspases in diseases, knowledge of therapeutic window and off target effects. A major accomplishment is Emricasan a...
A potent irreversible pan caspase inhibitor which is being evaluated in clinical trials for treatment of liver diseases. It has demonstrated significant tissue specificity with no effects on healthy individuals61. Appreciable number peptidomimetics and small molecule inhibitors have been identified as either specific or pan caspase inhibitors62. Several published reports on caspase inhibition are either significant findings or in initial phase of development and their clinical efficacy is yet unexplored. In in vitro and in vivo models catechin derivatives were found to suppress apoptosis in hepatocytes by inhibiting caspase-363. Isatin analog compounds have inhibited caspase-3 effectively in in vitro enzyme assays using recombinant enzyme and in HeLa cells treated with cyclosporine64. Kaempferol demonstrated dose dependent inhibition of caspase 3/7 activity and exhibited anti-apoptotic against multiple cell death stimuli like BFA, tunicamycin, CDDO-Me, staurosporine, doxorubicin, TNFα and cycloheximide in various cell lines. Nevertheless, kaempferol may target other molecules as well. For instance, screening for DAPK1 specific inhibitors recently identified kaempferol as one of flavonoids interacting with DAPK1 for which efficacy in cell lines is yet unknown65. The loss and gain of function of DAPK1 is associated with various cancer and neurodegenerative diseases respectively66. Kaempferol has been shown to inhibit NADPH oxidase directly and thereby preventing PC12 cells from 4-hydroxynonenal (HNE) induced apoptosis 67. Despite these previously known targets, we propose caspase inhibition as kaempferol’s mode of action that promotes survival in IMR32 cells because the contribution of these targets may not account for cell death induced by various stimuli we used in our study. Kaempferol inhibited ER stress and caspase 3 activation induced by ischemia reperfusion in cardiomyocytes and ex vivo model68. To the best of our knowledge, our study is the first report to demonstrate the activity of kaempferol against ER stress specific inducers and the mechanism of action of kaempferol in neuronal cells.

Table 1. Kinetics parameter of Caspase-3 enzyme activity in presence of Kaempferol.

| Kaempferol (µM) | 0.0  | 0.1  | 1.0  | 50   |
|----------------|------|------|------|------|
| Vmax           | 4.309e+006 | 7.536e+006 | 1.056e+007 | 2.086e+007 |
| Km             | 120.9 | 334.2 | 507.7 | 1663  |

Figure 8. Graphical abstract. Kaempferol alleviates ER stress by inhibiting the executioner caspase 3/7. Endogenous inhibitor of apoptotic proteins-IAPs level did not get altered upon kaempferol treatment and the SMAC mimetics which are inhibitor of IAPs reverses the kaempferol mediated caspase inhibition and allows cell death to occur.
In conclusion, kaempferol can be developed into a therapeutic agent specifically for neurodegenerative diseases as there is increased ER stress, inflammation and oxidative stress causing disease driven loss of cells. It is worth to note that kaempferol has been shown to inhibit all these processes in various cell types. We present our preliminary finding on caspase inhibition by kaempferol; however, further crystallography validation is a prime requisite. After which, kaempferol could be an ideal candidate to investigate the pharmacological aspect in in vivo disease conditions wherein caspase dependent cell death is involved.

Materials and Methods
Reagents. Brefeldin A, Tunicamycin, Q-RT PC and Dimethyl sulphoxide (DMSO) were purchased from Sigma Aldrich. DMEM, Fetal Bovine Serum, Antibiotic and Antimycotic solution, MTT and HiPurA RNA isolation kit were obtained from HiMedia, India. Kaempferol was purchased from Natural Remedies Pvt. Ltd., Bangalore. DPN (2,3-Bis(4-hydroxyphenyl)-propionitrile), PHTPP were purchased from Alfa Aesar (Hyderabad, India) and Cayman Chemicals, USA respectively. GDC0152, LC161 and Z-VAD-FMK from MedChem express, USA. CellTiter – Glo Luminescent cell viability assay kit, Caspase - Glo 3/7 assay kit, cDNA conversion kit was obtained from Applied Biosystems, India. SYBR Premix Ex Taq kit was purchased from TaKaRa Bio-India, India. Antibodies were purchased from Cell Signaling Technology, Danvers, MA, USA and Novus Biologicals, USA. For MTT assays, polystyrene, flat bottom and clear wells plates were used while for luminescence based assays solid white plates were used.

Cell culture conditions. Human IMR32, MDAMB 468, HeLa, MCF7 and mouse Neuro2A cells obtained from NCCS, Pune, India were cultured in DMEM supplemented with 10% Fetal Bovine Serum and maintained at 37°C in an incubator with humidified atmosphere containing 5% CO₂ and 95% air. Antibiotic and Antimycotic solution was added to prevent microbial growth in the cell culture.

Cytotoxicity assays. MTT and CellTiter-Glo luminescent cell viability assays were performed to estimate the cell viability. For MTT assay, cells were plated at density of 5 × 10⁴ cells/well in 96 well plates on day 0. Next day, medium was removed from each well and then pre-treated with Kaempferol or other selected compounds for 90 minutes followed by treating the cells with ER stress inducers. After 24 h of incubation, 20 µl of MTT (20 mg/ml) was added to each well and then incubated back for 3 hours at 37°C in an incubator with humidified atmosphere containing 5% CO₂ and 95% air. The formazan product which was formed in the cell was dissolved with 100% spectrosopic grade DMSO. ELISA reader (BioRad) was used to read the absorbance at 570 nm. For CellTiter-Glo assay, same procedure was followed in a 96 wells plate (polystyrene, flat bottom and white plate) except of adding MTT. To this, CellTiter-Glo assay solution was added. After 5 minutes of incubation, luminescence was measured using Luminometer (Berthold, Germany). Alternatively cell viability was assessed with trypan blue dye exclusion assay. 5 × 10⁴ cells were seeded in a 24 well plate and treated with Brefeldin A or in combination with Kaempferol in triplicate. After 24 hour of incubation the cells were collected from media along with trypsinized cells and counted for blue stained cells for dead and transparent for live cells after 2 minute incubation with 0.4% trypan blue (w/v) dissolved in PBS.

Caspase 3/7 activity assay. Cells were plated at density of 8 × 10⁴ cells/well in a 96 well plate. Cells were incubated for overnight and pre-treatment with test compound, followed by treatment with ER stress inducers for specified hours. Caspase Glo-3/7 solution was added and incubated at 22°C for 30 minutes as specified by the manufacturer. Luminometer (Berthold) was used to measure the luminescence.

RNA extraction and Quantitative RT-PCR. Total RNA was extracted using HiPurA™ Total RNA Miniprep purification kit from Himedia laboratories. Subsequently, 2 µg of total RNA was converted into cDNA using Reverse Transcriptase and manufacturer’s instructions were followed. For QPCR (AB 7500, Step One), 2 µl of the RT product was used with gene specific primers in conjunction with SYBR green. Human 18s rRNA was used as internal control and relative gene expression was calculated using 2^−ΔΔCT method. List of primers used in this study is tabulated in Supplementary Table 2.

Immunoblotting. Immunoblotting was carried out as described earlier by Ravanan et al.21. In brief, cells were plated in 60 mm dishes at the density of 6 × 10⁴ cells/dish. After overnight incubation, cells were pre-treated with kaempferol for 90 min and then treated with BFA for various time points. Cells were, washed with ice cold PBS and lysed with RIPA buffer containing 1X Protease cocktail and 1X PhosSTOP. Total protein concentrations were quantified by Folin’s assay. Immunoblotting analysis was done by loading 50 µg of protein in each lane for SDS-PAGE. Antibodies used in this study were obtained from Cell Signalling Technology (Beta actin##8457, eIF2α##3597, Phospho-eIF2α##3959, p38 MAPK##8690 and Phospho-p38 MAPK##4511) and Abclonal (GRP78 #A0241). Densitometry analysis of developed blots were carried out using NIH-Image software and normalized with respect to β-actin as internal control.

Immunocytochemistry and Microscopy. Immunocytochemistry was carried out as described in the Cell signaling Technology (CST)guide. Briefly, 5 × 10⁴ cells/well were seeded in a 24 well plate. After overnight incubation, cells were treated with the compounds for indicated time. The cell were then washed with 1XPBS and fixed with 4% Formaldehyde for 15 min. The cells were washed again with 1XPBS and incubated with 0.5% skimmed milk containing 0.3% tritonX100 for blocking nonspecific binding, for 1 hour. Immunostaining was done using cIAP1 (#NB2-27190SS) and cIAP2 (#NB100-1666), XIAP (#NB100-56183) specific antibodies (Novus biologicals, USA) and Anti-rabbit Alexa Flour 594 (#8889, Cell Signaling Technologies, USA) as a secondary antibody. Phase contrast and fluorescence images of cells under treated and non-treated conditions were captured using EVOS FLoid imaging station (Thermo Fisher, USA) with 20X fluorite objective and LED light cubes containing...
hard coated filters (blue and red). For a particular protein expression study, imaging parameters were kept constant throughout the imaging no image modifications were done post imaging.

**Recombinant enzyme activity assay.** For enzyme inhibition assays, recombinant Caspase 3 enzyme was obtained from Enzo Life sciences, BIOMOL Cat. #SE-169 and Caspase 3/7 glo assay reagent from Promega. 2 units of enzyme was used per well in a reaction mixture formed with 10 mM HEPES and 0.1% BSA. Reduction in the amount of luminescence would reveal the extent of inhibition caused by the test compounds from cleaving the substrate Z-DEVD-amino luciferin by human recombinant caspase-3 enzyme. Non liner regression analysis for Michelis-Menton kinetics and Curve fit for sigmoidal dose response (variable slope) was done using GraphPad Prism 5.0.

**In silico analysis.** Docking studies were carried out using AutoDock Suite 4.0. In brief, X-ray crystallographic structure of caspase-3 (PDB ID: 3DEJ), caspase-7 (PDB ID: 4FEA) and caspase-9 (PDB ID: 1NW9) were used as the target receptor. Ligands were retrieved from PubChem database in their 3D conformer form and corrected for protonation. Non- polar hydrogens were assigned for macromolecule. Gasteiger charges were set for the ligands and Kollman charges were added for the receptor using AutoDock Tools 1.5.6. The macromolecule was kept rigid during docking study. Rotatable bonds for ligand molecules were assigned. A grid centre was made on centre of macromolecule covering the entire protein surface, which functioned as the search space. AutoDock 4.0 was carried out to generate the map files for the flexible atoms and Lamarckian Genetic algorithm was used to define the docking parameter file (DPF) for AutoDock 4.0. Validation for docking procedure was done by re-docking the ligand 0TE with the active caspase 7 structure solved by X-ray crystallography. The re-docked orientation was compared to the crystal structure of docked complex (PDB ID: 4FEA). Based on the non-bonded interactions, H-bonds, torsional and desolvation energies, binding energy of the complexes were calculated for the confirmation with best binding pose and minimum energy. The binding interactions were studied using LigPlot + v. 1.4 for 2D interactions. PyMol V.1.7.4 and UCSF Chimera 1.10.2 were used for studying 3D interactions.

**Statistical analysis.** All data are presented as the Standard error of mean (S.E.M) of at least two independent experiments. Statistical comparisons were performed using one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test (Grappap Prism, version 5.0) and p-value of less than 0.05 was considered statistically significant.

**References**

1. Elmore, S. Apoptosis: a review of programmed cell death. *Toxicol Pathol* 35, 495–516, https://doi.org/10.1080/01926230701320337 (2007).
2. Szegedzi, E., Logue, S. E., Gorman, A. M. & Samali, A. Mediators of endoplasmic reticulum stress-induced apoptosis. *EMBO Rep* 7, 880–885, https://doi.org/10.1038/sj.embor.7400779 (2006).
3. Sano, R. & Reed, J. C. ER stress-induced cell death mechanisms. *Biochim Biophys Acta* 1833, 3460–3470 (2013).
4. Ozcak, L. & Taba, I. Role of endoplasmic reticulum stress in metabolic disease and other disorders. *Annu Rev Med* 63, 317–328 (2012).
5. Kim, I., Xu, W. & Reed, J. C. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. *Nat Rev Drug Discov* 7, 1013–1030 (2008).
6. Sokka, A. L. et al. Endoplasmic reticulum stress inhibition protects against excitotoxic neuronal injury in the rat brain. *J Neurosci* 27, 901–908 (2007).
7. Kim, J. S. et al. Salubrinal, ER stress inhibitor, attenuates kainic acid-induced hippocampal cell death. *J Neural Transm (Vienna)* 121, 1233–1243 (2014).
8. Choi, S. K., Lim, M., Byeon, S. H. & Lee, Y. H. Inhibition of endoplasmic reticulum stress improves coronary artery function in the spontaneously hypertensive rats. *Sci Rep* 6, 31925 (2016).
9. Mohammed-Ali, Z. et al. Endoplasmic reticulum stress inhibition attenuates hypertensive chronic kidney disease through reduction in proteinuria. *Sci Rep* 7, 41572 (2017).
10. Kim, H. J. et al. Inhibition of endoplasmic reticulum stress alleviates lipopolysaccharide-induced lung inflammation through modulation of NF-kappaB/HIF-1alpha signaling pathway. *Sci Rep* 3, 1142 (2013).
11. Chandrika, B. B. et al. Endoplasmic Reticulum Stress-Induced Autophagy Provides Cytoprotection from Chemical Hypoxia and Oxidant Injury and Ameliorates Renal Ischemia-Reperfusion Injury. *PLoS One* 10, e0140025 (2015).
12. Nakka, V. P., Guasain, A. & Raghubir, R. Endoplasmic reticulum stress plays critical role in brain damage after cerebral ischemia/ reperfusion in rats. *Neurotox Res* 17, 189–202 (2010).
13. Begum, G., Harvey, L., Dixon, C. E. & Sun, D. ER stress and effects of DHA as an ER stress inhibitor. *Transl Stroke Res* 4, 635–642 (2013).
14. Rubovitch, V. et al. The neuroprotective effect of salubrinal in a mouse model of traumatic brain injury. *Neuromolecular Med* 17, 58–70 (2015).
15. Ohiri, S. S., Hetman, M. & Whittemore, S. R. Restoring endoplasmic reticulum homeostasis improves functional recovery after spinal cord injury. *Neurobiol Dis* 58, 29–37 (2013).
16. Zhu, Y. et al. Eif-2a protects brainstem motoneurons in a murine model of sleep apnea. *J Neurosci* 28, 2168–2178 (2008).
17. Chen, Y., Wu, Z., Zhao, S. & Xiang, R. Chemical chaperones reduce ER stress and adipose tissue inflammation in high fat diet-induced mouse model of obesity. *Sci Rep* 6, 27486 (2016).
18. Boyce, M. et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. *Science* 307, 935–939 (2005).
19. Kim, A. J., Shi, Y., Austin, R. C. & Wertz, G. H. Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycerone synthase kinase-3. *J Cell Sci* 118, 89–99 (2005).
20. Kim, J. et al. Chemical biology investigation of cell death pathways activated by endoplasmic reticulum stress reveals cytoprotective modulators of ASK1. *J Biol Chem* 284, 1593–1603 (2009).
21. Patridge, E., Gareiss, P., Kinch, M. S. & Hoyer, D. An analysis of FDA-approved drugs: natural products and their derivatives. *Drug Discov Today* 21, 204–207 (2016).
22. Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. *J Nat Prod* 75, 311–335 (2012).
23. Mishra, B. B. & Tiwari, V. K. Natural products: an evolving role in future drug discovery. *Eur J Med Chem* 46, 4769–4807 (2011).
24. Vasilevich, N. I., Kombarov, R. V., Genis, D. V. & Kirpichenok, M. A. Lessons from natural products chemistry can offer novel approaches for synthetic chemistry in drug discovery. *J Med Chem* 55, 7003–7009 (2012).
25. Liu, H. et al. The Natural Occurring Compounds Targeting Endoplasmic Reticulum Stress. *Evid Based Complement Alternat Med* **2016**, *7831282* (2016).

26. Gutierrez-Merino, C. et al. Neuroprotective actions of flavonoids. *Curr Med Chem* **18**, 1195–1212 (2011).

27. Vauzour, D., Vafeiadou, K., Rodriguez-Mateos, A., Rendeiro, C. & Spencer, J. P. The neuroprotective potential of flavonoids: a multiplicity of effects. *Genes Nutr* **3**, 115–126 (2008).

28. Calderon-Montano, J. M., Burgos-Moron, E., Perez-Guerrero, C. & Lopez-Lazaro, M. A review on the dietary flavonoid kaempferol. *Mini Rev Med Chem* **11**, 298–344 (2011).

29. Zhou, W., Yue, P., Khuri, F. R. & Sun, S. Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving INK activation. *Cancer Res* **68**, 7484–7492 (2008).

30. Reimertz, C., Kogel, D., Arai, M., Chittenden, T. & Prehn, J. H. Gene expression during ER stress-induced apoptosis in neurons: induction of the BH3-only protein Bbc3/PUMA and activation of the mitochondrial apoptosis pathway. *J Cell Biol* **162**, 587–597 (2003).

31. Wang, J., Fang, F., Huang, Z., Wang, Y. & Wong, C. Kaempferol is an estrogen-related receptor alpha and gamma inverse agonist. *FEBS Lett* **583**, 643–647 (2009).

32. Chaudhuri, N., Talwar, P., Parimisetty, A., Lefebvre d'Hellencourt, C. & Ravanan, P. A molecular web: endoplasmic reticulum stress, inflammation, and oxidative stress. *Front Cell Neurosci* **8**, 213 (2014).

33. Guo, H. et al. Kaempferol induces apoptosis in HepG2 cells via activation of the endoplasmic reticulum stress pathway. *Mol Med Rep* **13**, 2791–2800 (2016).

34. Luo, H., Rankin, G. O., Li, Z., Depriest, L. & Chen, Y. C. Kaempferol induces apoptosis in ovarian cancer cells through activating p53 in the intrinsic pathway. *Food Chem* **128**, 513–519 (2011).

35. Marfe, G. et al. Kaempferol induces apoptosis in two different cell lines via Akt inactivation, Bax and SIRT3 activation, and mitochondrial dysfunction. *J Cell Biochem* **106**, 643–650 (2009).

36. Sharma, V. et al. Kaempferol induces apoptosis in glioblastoma cells through oxidative stress. *Mol Cancer Ther* **6**, 2544–2553 (2007).

37. Benosman, S. et al. Interleukin-1 receptor-associated kinase-2 (IRAK2) is a critical mediator of endoplasmic reticulum (ER) stress signaling. *PLoS One* **8**, e64256 (2013).

38. Morishima, N., Nakanishi, K., Takenouchi, H., Shibata, T. & Yasuhiko, Y. An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. *J Biol Chem* **277**, 34287–34294 (2002).

39. Conte, D. et al. Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. *Mol Cell Biol* **26**, 699–708 (2006).

40. Kavanagh, E., Roddie, J., Burguillo, M. A., Venero, J. L. & Joseph, B. Regulation of caspase-3 processing by cIAP2 controls the switch between pro-inflammatory activation and cell death in microglia. *Cell Death Dis* **5**, e1565 (2014).

41. Harlin, H., Reffey, S. B., Duckett, C. S., Lindsten, T. & Thompson, C. B. Characterization of XIAP-deficient mice. *Mol Cell Biol* **21**, 3604–3608 (2001).

42. Flygare, J. A. et al. Discovery of a potent small molecule-antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). *J Med Chem* **55**, 4011–4112 (2012).

43. Ramakrishnan, V. et al. Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma. *Leukemia* **28**, 1519–1524 (2014).

44. Arafa el, S. A. et al. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. *Cancer Res* **69**, 8910–8917 (2009).

45. Das, A., Banik, N. L. & Ray, S. K. Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes. *Cancer* **116**, 164–176 (2010).

46. Sakao, K., Fujiy, M. & Hou, D. X. Clarification of the role of quercetin hydroxyl groups in superoxide generation and cell apoptosis by chemical modification. *Bioch Biophys Acta* **1791**, 2048–2053 (2009).

47. White, J. B. et al. Some natural flavonoids are competitive inhibitors of Caspase-1, -3, -7 and -9 despite their cellular toxicity. *Food Chem* **131**, 1453–1459 (2012).

48. Kroemer, G. & Martin, S. J. Caspase-dependent cell death. *Nat Med* **11**, 725–730 (2005).

49. Hardy, A. J., Lam, J., Nguyen, J. T., O’Brien, T. & Wells, J. A. Discovery of an allostERIC site in the caspases. *Proc Natl Acad Sci USA* **101**, 12461–12466 (2004).

50. Feldman, T. et al. A class of allostERIC caspase inhibitors identified by high-throughput screening. *Mol Cell* **47**, 585–595 (2012).

51. Walters, J., Schipper, J. L., Swartz, P., Mattos, C. & Clark, A. C. AllostERIC modulation of caspase 3 through mutagenesis. *Bioorg Med Chem Lett* **22**, 401–411 (2012).

52. Shiozaki, E. N. et al. Mechanism of XIAP-mediated inhibition of caspase-9. *Mol Cell* **11**, 519–527 (2003).

53. Walsh, J. A., Lam, J., Nguyen, J. T., O’Brien, T. & Wells, J. A. A class of allosteric caspase inhibitors identified by high-throughput screening. *Mol Cell* **47**, 585–595 (2012).

54. Walters, J., Schipper, J. L., Swartz, P., Mattos, C. & Clark, A. C. AllostERIC modulation of caspase 3 through mutagenesis. *Bioorg Med Chem Lett* **22**, 1631–1639 (2007).

55. Zhang, H., Li, H., Liu, X. & Bie, J. Effect of caspase-9 inhibition on endoplasmic reticulum stress induced cortical neuronal injury in rats. *Int J Clin Exp Med* **6**, 541–551 (2013).

56. Anana, V. S. et al. Uncovering a Dual Regulatory Role for Caspases During Endoplasmic Reticulum Stress-induced Cell Death. *Mol Cell Proteomics* **15**, 2293–2307 (2016).

57. Van Noorden, C. J. The history of Z-VAD-FMK, a tool for understanding the significance of caspase inhibition. *Acta Histochem* **103**, 241–251 (2001).

58. Howley, B. & Fearnhead, H. O. Caspases as therapeutic targets. *J Cell Mol Med* **12**, 1502–1516 (2008).

59. Shiffman, M. L. et al. Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C. *Aliment Pharmacol Ther* **31**, 969–978 (2010).

60. MacKenzie, S. H., Schipper, J. L. & Clark, A. C. The potential for caspases in drug discovery. *Curr Opin Drug Discov Devel* **13**, 568–576 (2010).

61. Katunuma, N. et al. Catechin derivatives: specific inhibitor for caspases-3, -7 and -9, and the prevention of apoptosis at the cell and animal levels. *FEBS Lett* **580**, 741–746 (2006).

62. Chu, W., Rothfuss, J., Zhou, D. & Mach, R. H. Synthesis and evaluation of isatin analogs as caspase-3 inhibitors: introduction of a hydrophilic group increases potency in a whole cell assay. *Biorg Med Chem Lett* **21**, 2192–2197 (2011).

63. Yokoyama, T., Kosaka, Y. & Mizuguchi, M. Structural Insight into the Interactions between Death-Associated Protein Kinase 1 and Natural Flavonoids. *J Med Chem* **58**, 7400–7408 (2015).

64. Singh, P., Ravanani, P. & Talwar, P. Death Associated Protein Kinase 1 (DAPK1): A Regulator of Apoptosis and Autophagy. *Front Mol Neurosci* **9**, 46 (2016).

65. Jang, Y. J. et al. Kaempferol attenuates 4-hydroxynonenal-induced apoptosis in PC12 cells by directly inhibiting NADPH oxidase. *J Pharmacol Exp Ther* **337**, 747–754 (2011).
68. Kim, D. S. et al. Kaempferol protects ischemia/reperfusion-induced cardiac damage through the regulation of endoplasmic reticulum stress. *Immunopharmacol Immunotoxicol* **30**, 257–270 (2008).
69. Deveraux, Q. L. & Reed, J. C. IAP family proteins—suppressors of apoptosis. *Genes Dev* **13**, 239–252 (1999).
70. Hamanaka, R. B., Bobrovnikova-Marjon, E., Ji, X., Liebhaber, S. A. & Diehl, J. A. PERK-dependent regulation of IAP translation during ER stress. *Oncogene* **28**, 910–920 (2009).
71. Ravanan, P. et al. Synthetic triterpenoid cyano enone of methyl boswellate activates intrinsic, extrinsic, and endoplasmic reticulum stress cell death pathways in tumor cell lines. *Mol Cancer Ther* **10**, 1635–1643 (2011).

Acknowledgements

PR greatly acknowledges the financial support from Science and Engineering Research Board (SB/FT/LS-419/2012), Department of Science and Technology, India.

Author Contributions

P.R. designed the experiments and A.A. performed the experiments. Data analysis and manuscript preparation was done by P.R. and A.A.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-20499-7.

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018